Homology Medicines, Inc. (FIXX)
| Market Cap | 590.25M |
| Revenue (ttm) | 2.29M |
| Net Income (ttm) | -123.07M |
| Shares Out | 45.23M |
| EPS (ttm) | -2.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $13.04 |
| Previous Close | $13.59 |
| Change ($) | -0.55 |
| Change (%) | -4.05% |
| Day's Open | 13.69 |
| Day's Range | 13.01 - 13.92 |
| Day's Volume | 228,645 |
| 52-Week Range | 8.92 - 22.04 |
Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeuti...
Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.46% and 126.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...
- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase -
Homology Medicines (FIXX) is making news on Monday after announcing a massive $60 million investment deal with Pfizer (PFE) The post Homology Medicines News: 9 Things for FIXX Stock Investors ...
- Marked Reductions in Phe Observed at Two Dose s -
Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
San Francisco, California--(Newsfile Corp. - October 29, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The fi...
San Francisco, California--(Newsfile Corp. - October 27, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The fi...
HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Show ed Improvements in Key Disease Biomarkers
Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of invest...
San Francisco, California--(Newsfile Corp. - October 20, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The fi...
San Francisco, California--(Newsfile Corp. - October 16, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The f...
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz continues its investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on be...
New York, New York--(Newsfile Corp. - October 15, 2020) - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders...
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of I...
BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTIONS--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on beh...
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of I...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homology Medicines, Inc. (N...
BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virt...
Homology Medicines (FIXX) delivered earnings and revenue surprises of 3.70% and 20.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Executive with Extensive Rare Disease Expertise in Global Finance and Commercial Operations -
Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- Methods Showed Efficient On-Target Gene Integration with No Unintended DNA Modifications -
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.
- Molecular Methods Quantified Precision and Efficiency of Nuclease-Free Gene Editing for PKU -
Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
- Data Package Supported Initiation of Ongoing pheNIX Clinical Trial for Adults with PKU -
Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the...
Shares of genetic therapy company Homology Medicines Inc (NASDAQ: FIXX) were moving to the downside Wednesday.
- Well-Tolerated in First-in-Human AAVHSC Gene Therapy Trial -
- Experienced Clinical Geneticist with Track Record in Rare Disease Drug Development Joins Homology’s Senior Management -
BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its propriet...
Homology Medicines (FIXX) delivered earnings and revenue surprises of -15.52% and 17.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for t...
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AAVHSCs Showed Consistent Therapeutic Effect Across All Empty to Full Capsid Ratios, and Improved Benefit in the PKU Murine Model Compared to AAV5 AAVHSCs Showed Consistent Therapeutic Effect ...
BEDFORD, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that support its ...
BEDFORD, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today presentations at the following industry, investor and...
BEDFORD, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcom...
Homology Medicines (FIXX) delivered earnings and revenue surprises of -16.36% and -73.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the ...
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About FIXX
Homology Medicines, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, cen... [Read more...]
| Industry Biotechnology | Founded 2015 |
| CEO Arthur Tzianabos | Employees 206 |
| Stock Exchange NASDAQ | Ticker Symbol FIXX |
Financial Performance
In 2019, FIXX's revenue was $1.67 million, a decrease of -68.70% compared to the previous year's $5.32 million. Losses were -$103.92 million, 87.0% more than in 2018.
Analyst Forecasts
According to 10 analysts, the average rating for FIXX stock is "Strong Buy." The 12-month stock price forecast is 28.44, which is an increase of 118.10% from the latest price.